Bausch Health Q2 Revenue Hits $2.85B, Raises Full-Year Guidance
BHC is trading near its 52-week low of $4.33 (13% above the low).
Summary
Bausch Health delivered a strong Q2 with consolidated revenue of $2.85 billion, up 13% reported and 11% organic. GAAP EPS jumped to $0.68 from $0.40, and adjusted EPS surged 40% to $1.26. Adjusted EBITDA grew 28% to $1.075 billion. The core business excluding Bausch + Lomb posted its 13th straight quarter of growth, with revenue up 16% and adjusted EBITDA up 28%. Management raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow, signaling confidence in sustained momentum. This follows a Q1 marred by a $1.43 billion goodwill impairment; the Q2 rebound and guidance raise suggest the underlying business is recovering faster than feared. The Salix segment led with 21% growth, driven by Xifaxan. With a market cap near $1.75 billion, these results materially improve the earnings trajectory and could prompt a re-rating.
At the time of this announcement, BHC was trading at $4.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.33 to $8.69. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.